Neurozen is dedicated to developing advanced, deep learning-enabled neuroimaging and genetic solutions for the risk assessment and early detection of Alzheimer’s disease. Risk assessment and early detection are crucial to helping target the disease before irreversible brain damage or mental decline has occurred. Our mission is to provide innovative, quality clinical tools to predict, quantify, and monitor neurodegeneration as well as so that physicians can be more confident in making important clinical decisions and people can enjoy a higher quality of life.